Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Przegl Lek ; 69(1): 29-33, 2012.
Artigo em Polonês | MEDLINE | ID: mdl-22764516

RESUMO

Testosterone deficiency syndrome is being seen in increasing percentage of men with middle and old age. Besides the typical deterioration of sexual function there is predisposition to metabolic syndrome and increased risk of cardiovascular diseases. The similarity of the effects of testosterone substitution and the dietary treatment led the authors to a retrospective analysis of patient data treated for testosterone deficiency syndrome. Data on 341 patients aged over 45 years with metabolic syndrome and diabetes, meeting criteria for the diagnosis of testosterone deficiency syndrome were divided into 5 groups: T--testosterone substitution without additional diet, T-Low-Carb--testosterone and low carbohydrate diet, T-Fat-Low--testosterone and low fat diet, Carb-Low--only low carbohydrate diet, Fat-Low--only low fat diet. We analyzed change in body weight, waist circumference, blood pressure, fasting glucose, HbAlc, HDL cholesterol and triglyceride levels within 6 months from the start of observation. The best results of all investigated parameters were obtained in patients treated with testosterone and low-carbohydrate diet and in the group treated with testosterone and low-fat diet. Slightly worse results in the group received the same diets and the worst in the group treated only with testosterone. The improvement obtained in the total testosterone therapy and diet was much greater than the simple sum of the effects of both methods witch suggests the existence of synergies.


Assuntos
Síndrome Metabólica/dietoterapia , Síndrome Metabólica/tratamento farmacológico , Testosterona/deficiência , Testosterona/uso terapêutico , Idoso , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Dieta com Restrição de Carboidratos , Dieta com Restrição de Gorduras , Humanos , Masculino , Síndrome Metabólica/sangue , Pessoa de Meia-Idade , Estudos Retrospectivos , Triglicerídeos/sangue
2.
Neuro Endocrinol Lett ; 33(7): 697-702, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23391877

RESUMO

OBJECTIVES: Premature ovarian failure (POF) is a consequence of gonadotoxic chemoradiotherapy given in antyneoplasia treatment. In young women it will correlate with menopausal symptoms which tend to appear due to depleted ovarian follicle reserve. DESIGN: It was a case series study that included women 18-50 years old who were treated for malignancy with gonadotoxic chemioradiotherapy. We have measured blood hormonal levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and progesterone within one month of various hormone replacement therapy (HRT). RESULTS: We have observed different kind of hormonal reaction according to FSH, LH, estradiol and progesterone levels due to various hormonal replacement therapy. The administration of various HRT regimens presented with a decrease in the blood concentration of estradiol E2 and progesterone and a concomitant increase of FSH and LH. These findings demonstrate a shift to physiological ranges and a simultaneous improvement of symptoms associated with CI-POF. CONCLUSIONS: The most appropriate therapy needs to be selected according to the patient's alleviation of symptoms and correction of blood hormone levels.


Assuntos
Quimiorradioterapia/efeitos adversos , Neoplasias Hematológicas/terapia , Terapia de Reposição Hormonal/métodos , Insuficiência Ovariana Primária/induzido quimicamente , Insuficiência Ovariana Primária/tratamento farmacológico , Adolescente , Adulto , Anticoncepcionais Femininos/administração & dosagem , Combinação de Medicamentos , Didrogesterona/administração & dosagem , Estradiol/administração & dosagem , Estradiol/sangue , Estriol/administração & dosagem , Feminino , Hormônio Foliculoestimulante Humano/sangue , Humanos , Infertilidade Feminina/sangue , Infertilidade Feminina/induzido quimicamente , Infertilidade Feminina/tratamento farmacológico , Hormônio Luteinizante/sangue , Acetato de Medroxiprogesterona/administração & dosagem , Megestrol/administração & dosagem , Megestrol/análogos & derivados , Pessoa de Meia-Idade , Folículo Ovariano/efeitos dos fármacos , Insuficiência Ovariana Primária/sangue , Progesterona/sangue , Congêneres da Progesterona/administração & dosagem , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA